Cargando…

Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction

BACKGROUND: The benefit of ivabradine as an adjunctive therapy to conventional treatment in patients with heart failure (HF) with reduced ejection fraction (HFrEF) is a reduction in both cardiovascular death and HF hospitalization. This study aimed to analyze the cost-effectiveness of ivabradine plu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krittayaphong, Rungroj, Yadee, Jirawit, Permsuwan, Unchalee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901001/ https://www.ncbi.nlm.nih.gov/pubmed/31824183 http://dx.doi.org/10.2147/CEOR.S226568

Ejemplares similares

Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand
por: Krittayaphong, Rungroj, et al.
Publicado: (2021)

Discounting money and health effects from communicable and noncommunicable diseases in Thailand
por: Yadee, Jirawit, et al.
Publicado: (2023)

Cost–Utility Analysis of Transcatheter Aortic Valve Implantation versus Surgery in High-Risk Severe Aortic Stenosis Patients in Thailand
por: Permsuwan, Unchalee, et al.
Publicado: (2022)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
por: Lee, Ying‐Hsiang, et al.
Publicado: (2021)

Effect of ivabradine on ventricular arrhythmias in heart failure patients with reduced ejection fraction
por: Pay, Levent, et al.
Publicado: (2023)

Impact of different degrees of left ventricular strain on left atrial mechanics in heart failure with preserved ejection fraction
por: Songsangjinda, Thammarak, et al.
Publicado: (2022)

Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Heart Failure in Thailand
por: Permsuwan, Unchalee, et al.
Publicado: (2020)

Role of Ivabradine in Patients with Heart Failure with Preserved Ejection Fraction
por: Nadeem, Muhammad, et al.
Publicado: (2020)

Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2023)

Correction to: Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2023)

Ivabradine in heart failure patients with reduced ejection fraction and history of paroxysmal atrial fibrillation
por: Lin, Yu‐Sheng, et al.
Publicado: (2022)

Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis
por: Treewaree, Sukrit, et al.
Publicado: (2023)

Successful treatment with ivabradine in a β‐blocker‐refractory patient with acute decompensated heart failure with reduced ejection fraction
por: Inoue, Tomoko, et al.
Publicado: (2023)

The role of Ivabradine in Diastolic Heart Failure with preserved Ejection Fraction. A Doppler-Echocardiographic study
por: Cacciapuoti, Federico, et al.
Publicado: (2017)

Effect of ivabradine on hospitalization of heart failure patients with reduced left ventricular ejection fraction: A retrospective cohort study
por: Al-Balushi, Sara, et al.
Publicado: (2020)

Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta‐analysis of randomized controlled trials
por: Bryan Richard, Sasmita, et al.
Publicado: (2021)

Ivabradine Ameliorates Cardiac Function in Heart Failure with Preserved and Reduced Ejection Fraction via Upregulation of miR-133a
por: Shao, Shuai, et al.
Publicado: (2021)

Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
por: Isaza, Nicolas, et al.
Publicado: (2021)

Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
por: McMurray, John J V, et al.
Publicado: (2018)

Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
por: Sang, Haiqiang, et al.
Publicado: (2022)

Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.
por: Bouabdallaoui, Nadia, et al.
Publicado: (2019)

Cost‐Effectiveness of Ivabradine for Heart Failure in the United States
por: Kansal, Anuraag R., et al.
Publicado: (2016)

Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction
por: Chaudhary, Ammar G., et al.
Publicado: (2021)

Insights into foundational therapies for heart failure with reduced ejection fraction
por: McMurray, John J. V., et al.
Publicado: (2022)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
por: Liu, Dan, et al.
Publicado: (2023)

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

Management of heart failure with reduced ejection fraction
por: Haydock, Paul M, et al.
Publicado: (2022)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Impact of adjunctive tolvaptan on sympathetic activity in acute heart failure with preserved ejection fraction
por: Tamaki, Shunsuke, et al.
Publicado: (2020)

Ivabradine tolerability in heart failure
por: Birkhoelzer, Sarah, et al.
Publicado: (2018)

Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy
por: Rahamim, Eldad, et al.
Publicado: (2021)

A Phase 4, Open-Label, Single-Arm Study Assessing the Efficacy and Safety of Ivabradine in African American Patients with Heart Failure and Reduced Ejection Fraction
por: Lanfear, David E., et al.
Publicado: (2020)

Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction
por: Straw, Sam, et al.
Publicado: (2021)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines
por: Mendoza, Victor L., et al.
Publicado: (2021)

Treatment Costs for Patients with Chronic Kidney Disease Who Received Multidisciplinary Care in a District Hospital in Thailand
por: Songsermlosakul, Suwaporn, et al.
Publicado: (2020)

Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction
por: Al‐Mohammad, Abdallah
Publicado: (2019)

Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly
por: Milinković, Ivan, et al.
Publicado: (2022)

Role of interleukins in heart failure with reduced ejection fraction
por: Segiet, Oliwia Anna, et al.
Publicado: (2019)

Updates in pharmacotherapy of heart failure with reduced ejection fraction
por: Espinoza, Clifton, et al.
Publicado: (2021)

Editorial: Edema in heart failure with reduced ejection fraction
por: Gladysheva, Inna P., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rbb47n8dcc7cm92v868m27k1oc